FDA
-
-
-
-
-
-
-
Merck and Gilead discontinue lung cancer drug combination trial
-
-
-
-
-
-
-
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
-
-
-
-
-
-
-
FDA approves Merck's IDVYNSO for HIV-1 treatment switch
-
-
-
-
-
-
-
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Pat
-
-
-
-
-
-
-
Merck drug shows superior cholesterol reduction in phase 3 trial
-
-
-
-
-
-
-
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
-
-
-
-
-
-
-
NeOnc Technologies sets phase 2 dose for brain cancer drug NEO212
-
323,879 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

